Mesoblast's allogeneic stem cells in trial for diabetic retinopathy and age-related macular degeneration.

A research director at Los Alamos National Laboratories said the addition of a peta-scale supercomputer is as big a leap forward as when scientists got their hands on their first computer ever.

Engineers and technicians at IBM are assembling the final pieces of what they hope will soon become the world's most powerful supercomputer - doubling the speed of the today's fastest machine.

Two local antibody therapeutics businesses have agreed to join forces.

CLC bio has released the CLC Bioinformatics Cell, which enables users to transform their ordinary Intel- or AMD-based workstation computers to super-computing units.

IBM's Blue Gene has retained its position as the most powerful computer in the world.

An experimental drug designed to seek out and destroy a gene associated with vascular disease is providing effective in early animal trials.

Shareholders in Regenera (ASX:RGA) have been asked to attend a meeting in Perth between Christmas and New Year, as the company seeks to revise terms of its planned merger with US firm Advanced Ocular Systems (AOS).

Melbourne-based biopharma BioDiem (ASX:BDM) has received regulatory approval to commence a phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.

Antisense Therapeutics (ASX:ANP) has claimed successful results from animal studies targeting the growth hormone receptor with an antisense drug, designed to reduce the growth of new blood vessels that can lead to two eye diseases which are major causes of blindness.

Scientists, industry and government are doing their bit to develop the Australian biotechnology industry, writes Peter Andrews -- so where are the investors?